RecruitingPhase 1NCT07062549

Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell

First-in-Human Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Enrollment

6 participants

Start Date

Jan 26, 2022

Study Type

INTERVENTIONAL

Conditions

Renal Cell Carcinoma (Kidney Cancer)

Summary

This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new imaging agent (111In-XYIMSR-01) used with SPECT/CT scanning — a type of nuclear medicine imaging — to detect and map tumors in people with metastatic clear cell kidney cancer, which may help guide future targeted treatment. **You may be eligible if...** - You are 18 years or older - You have kidney cancer confirmed as the clear cell type by tissue testing - You have between 2 and 10 tumor sites measurable on standard CT or MRI scans - Your liver, kidney, and blood count lab values are within acceptable limits **You may NOT be eligible if...** - You have fewer than 2 or more than 10 measurable tumor sites - Your kidney, liver, or blood count function is significantly impaired - You are unable or unwilling to comply with the study procedures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.